Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients
Objective To evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19. Methods We present a post hoc analysis from a double-blinded placebo-controlled randomized clinical trial (RCT) on the effect of colchicine for the treatm...
Saved in:
| Published in | Inflammation research Vol. 72; no. 5; pp. 895 - 899 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cham
Springer International Publishing
01.05.2023
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Objective
To evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19.
Methods
We present a post hoc analysis from a double-blinded placebo-controlled randomized clinical trial (RCT) on the effect of colchicine for the treatment of COVID-19. Serum levels of NOD-like receptor protein 3 (NLRP3) inflammasome products—active caspase-1 (Casp1p20), IL-1β, and IL-18—were assessed at enrollment and after 48–72 h of treatment in patients receiving standard-of-care (SOC) plus placebo vs. those receiving SOC plus colchicine. The colchicine regimen was 0.5 mg tid for 5 days, followed by 0.5 mg bid for another 5 days.
Results
Thirty-six patients received SOC plus colchicine, and thirty-six received SOC plus placebo. Colchicine reduced the need for supplemental oxygen and the length of hospitalization. On Days 2–3, colchicine lowered the serum levels of Casp1p20 and IL-18, but not IL-1β.
Conclusion
Treatment with colchicine inhibited the activation of the NLRP3 inflammasome, an event triggering the ‘cytokine storm’ in COVID-19.
Trial registration numbers
RBR-8jyhxh |
|---|---|
| AbstractList | ObjectiveTo evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19.MethodsWe present a post hoc analysis from a double-blinded placebo-controlled randomized clinical trial (RCT) on the effect of colchicine for the treatment of COVID-19. Serum levels of NOD-like receptor protein 3 (NLRP3) inflammasome products—active caspase-1 (Casp1p20), IL-1β, and IL-18—were assessed at enrollment and after 48–72 h of treatment in patients receiving standard-of-care (SOC) plus placebo vs. those receiving SOC plus colchicine. The colchicine regimen was 0.5 mg tid for 5 days, followed by 0.5 mg bid for another 5 days.ResultsThirty-six patients received SOC plus colchicine, and thirty-six received SOC plus placebo. Colchicine reduced the need for supplemental oxygen and the length of hospitalization. On Days 2–3, colchicine lowered the serum levels of Casp1p20 and IL-18, but not IL-1β.ConclusionTreatment with colchicine inhibited the activation of the NLRP3 inflammasome, an event triggering the ‘cytokine storm’ in COVID-19.Trial registration numbersRBR-8jyhxh Objective To evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19. Methods We present a post hoc analysis from a double-blinded placebo-controlled randomized clinical trial (RCT) on the effect of colchicine for the treatment of COVID-19. Serum levels of NOD-like receptor protein 3 (NLRP3) inflammasome products—active caspase-1 (Casp1p20), IL-1β, and IL-18—were assessed at enrollment and after 48–72 h of treatment in patients receiving standard-of-care (SOC) plus placebo vs. those receiving SOC plus colchicine. The colchicine regimen was 0.5 mg tid for 5 days, followed by 0.5 mg bid for another 5 days. Results Thirty-six patients received SOC plus colchicine, and thirty-six received SOC plus placebo. Colchicine reduced the need for supplemental oxygen and the length of hospitalization. On Days 2–3, colchicine lowered the serum levels of Casp1p20 and IL-18, but not IL-1β. Conclusion Treatment with colchicine inhibited the activation of the NLRP3 inflammasome, an event triggering the ‘cytokine storm’ in COVID-19. Trial registration numbers RBR-8jyhxh To evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19.OBJECTIVETo evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19.We present a post hoc analysis from a double-blinded placebo-controlled randomized clinical trial (RCT) on the effect of colchicine for the treatment of COVID-19. Serum levels of NOD-like receptor protein 3 (NLRP3) inflammasome products-active caspase-1 (Casp1p20), IL-1β, and IL-18-were assessed at enrollment and after 48-72 h of treatment in patients receiving standard-of-care (SOC) plus placebo vs. those receiving SOC plus colchicine. The colchicine regimen was 0.5 mg tid for 5 days, followed by 0.5 mg bid for another 5 days.METHODSWe present a post hoc analysis from a double-blinded placebo-controlled randomized clinical trial (RCT) on the effect of colchicine for the treatment of COVID-19. Serum levels of NOD-like receptor protein 3 (NLRP3) inflammasome products-active caspase-1 (Casp1p20), IL-1β, and IL-18-were assessed at enrollment and after 48-72 h of treatment in patients receiving standard-of-care (SOC) plus placebo vs. those receiving SOC plus colchicine. The colchicine regimen was 0.5 mg tid for 5 days, followed by 0.5 mg bid for another 5 days.Thirty-six patients received SOC plus colchicine, and thirty-six received SOC plus placebo. Colchicine reduced the need for supplemental oxygen and the length of hospitalization. On Days 2-3, colchicine lowered the serum levels of Casp1p20 and IL-18, but not IL-1β.RESULTSThirty-six patients received SOC plus colchicine, and thirty-six received SOC plus placebo. Colchicine reduced the need for supplemental oxygen and the length of hospitalization. On Days 2-3, colchicine lowered the serum levels of Casp1p20 and IL-18, but not IL-1β.Treatment with colchicine inhibited the activation of the NLRP3 inflammasome, an event triggering the 'cytokine storm' in COVID-19.CONCLUSIONTreatment with colchicine inhibited the activation of the NLRP3 inflammasome, an event triggering the 'cytokine storm' in COVID-19.RBR-8jyhxh.TRIAL REGISTRATION NUMBERSRBR-8jyhxh. To evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19. We present a post hoc analysis from a double-blinded placebo-controlled randomized clinical trial (RCT) on the effect of colchicine for the treatment of COVID-19. Serum levels of NOD-like receptor protein 3 (NLRP3) inflammasome products-active caspase-1 (Casp1p20), IL-1β, and IL-18-were assessed at enrollment and after 48-72 h of treatment in patients receiving standard-of-care (SOC) plus placebo vs. those receiving SOC plus colchicine. The colchicine regimen was 0.5 mg tid for 5 days, followed by 0.5 mg bid for another 5 days. Thirty-six patients received SOC plus colchicine, and thirty-six received SOC plus placebo. Colchicine reduced the need for supplemental oxygen and the length of hospitalization. On Days 2-3, colchicine lowered the serum levels of Casp1p20 and IL-18, but not IL-1β. Treatment with colchicine inhibited the activation of the NLRP3 inflammasome, an event triggering the 'cytokine storm' in COVID-19. RBR-8jyhxh. |
| Author | Rodrigues, T. S. Miranda, C. H. Cunha, F. Q. Veras, F. P. Zamboni, D. S. Almeida, S. C. L. Cunha, T. M. Bonjorno, L. P. Dib, S. M. Louzada-Junior, P. Bollela, V. R. Cunha, L. D. Borges, M. C. Arruda, E. Sousa, B. A. Giannini, M. C. Vilar, F. C. Gigante, S. L. G. Pazin-Filho, A. Menezes, P. I. S. O. Santana, R. C. Amaral, N. B. Leiria, L. O. S. Fonseca, B. A. L. Auxiliadora-Martins, M. Schneider, A. H. Benatti, M. N. Emrich-Filho, L. L. Del-Ben, C. M. Lopes, M. I. Luppino-Assad, R. Alves-Filho, J. C. Oliveira, R. D. R. Rezek, U. C. |
| Author_xml | – sequence: 1 givenname: N. B. surname: Amaral fullname: Amaral, N. B. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 2 givenname: T. S. surname: Rodrigues fullname: Rodrigues, T. S. organization: Department of Cell Biology, University of São Paulo – sequence: 3 givenname: M. C. surname: Giannini fullname: Giannini, M. C. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 4 givenname: M. I. surname: Lopes fullname: Lopes, M. I. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 5 givenname: L. P. surname: Bonjorno fullname: Bonjorno, L. P. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 6 givenname: P. I. S. O. surname: Menezes fullname: Menezes, P. I. S. O. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 7 givenname: S. M. surname: Dib fullname: Dib, S. M. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 8 givenname: S. L. G. surname: Gigante fullname: Gigante, S. L. G. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 9 givenname: M. N. surname: Benatti fullname: Benatti, M. N. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 10 givenname: U. C. surname: Rezek fullname: Rezek, U. C. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 11 givenname: L. L. surname: Emrich-Filho fullname: Emrich-Filho, L. L. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 12 givenname: B. A. surname: Sousa fullname: Sousa, B. A. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 13 givenname: S. C. L. surname: Almeida fullname: Almeida, S. C. L. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 14 givenname: R. surname: Luppino-Assad fullname: Luppino-Assad, R. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 15 givenname: F. P. surname: Veras fullname: Veras, F. P. organization: Department of Pharmacology, University of São Paulo – sequence: 16 givenname: A. H. surname: Schneider fullname: Schneider, A. H. organization: Department of Pharmacology, University of São Paulo – sequence: 17 givenname: L. O. S. surname: Leiria fullname: Leiria, L. O. S. organization: Department of Pharmacology, University of São Paulo – sequence: 18 givenname: L. D. surname: Cunha fullname: Cunha, L. D. organization: Department of Cell Biology, University of São Paulo – sequence: 19 givenname: J. C. surname: Alves-Filho fullname: Alves-Filho, J. C. organization: Department of Pharmacology, University of São Paulo – sequence: 20 givenname: T. M. surname: Cunha fullname: Cunha, T. M. organization: Department of Pharmacology, University of São Paulo – sequence: 21 givenname: E. surname: Arruda fullname: Arruda, E. organization: Department of Cell Biology, University of São Paulo – sequence: 22 givenname: C. H. surname: Miranda fullname: Miranda, C. H. organization: Department of Emergency Medicine, University of São Paulo – sequence: 23 givenname: A. surname: Pazin-Filho fullname: Pazin-Filho, A. organization: Department of Emergency Medicine, University of São Paulo – sequence: 24 givenname: M. surname: Auxiliadora-Martins fullname: Auxiliadora-Martins, M. organization: Department of Surgery and Anatomy, University of São Paulo – sequence: 25 givenname: M. C. surname: Borges fullname: Borges, M. C. organization: Department of Emergency Medicine, University of São Paulo – sequence: 26 givenname: B. A. L. surname: Fonseca fullname: Fonseca, B. A. L. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 27 givenname: V. R. surname: Bollela fullname: Bollela, V. R. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 28 givenname: C. M. surname: Del-Ben fullname: Del-Ben, C. M. organization: Department of Neuroscience and Behavior Ribeirao Preto Medical School, University of São Paulo – sequence: 29 givenname: F. Q. surname: Cunha fullname: Cunha, F. Q. organization: Department of Pharmacology, University of São Paulo – sequence: 30 givenname: R. C. surname: Santana fullname: Santana, R. C. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 31 givenname: F. C. surname: Vilar fullname: Vilar, F. C. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 32 givenname: D. S. surname: Zamboni fullname: Zamboni, D. S. organization: Department of Cell Biology, University of São Paulo – sequence: 33 givenname: P. surname: Louzada-Junior fullname: Louzada-Junior, P. organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo – sequence: 34 givenname: R. D. R. surname: Oliveira fullname: Oliveira, R. D. R. email: renedroliveira@gmail.com organization: Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36917217$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUtv1DAUhS1URB_wB1igSGzYBHzteGyvEBpelUYtQoDYWTeO03GV2FM7qTT_HrfTB-2iK9u63zn3-N5DshdicIS8BvoeKJUfMqUUoKaM1xQkqHr7jBxAw2itqfq7V-5XJa443SeHOZ8XXDHFXpB9vtAgGcgDslrGwa699cFVyXWzdbma1q5CO_lLnHwMVeyrk9XPH7zyoR9wHDHH0ZVHtTz9c_y5Bl1tCujClF-S5z0O2b26OY_I769ffi2_16vTb8fLT6vaNlJMNUfFETuphbR9J6DTnPYL22rkbesQQEiJrUTWonCKAldCOoa6EYBaWc2PyMed72ZuR9fZ0jvhYDbJj5i2JqI3DyvBr81ZvDRlbMCZlsXh3Y1Dihezy5MZfbZuGDC4OGfDpFooYFw0BX37CD2Pcwrlf4YpEKphQvBCvfk_0l2W20kXQO0Am2LOyfXG-ul6wCWhH0q0q3TS7JZqyubM9VLNtkjZI-mt-5MivhPlAoczl-5jP6H6Bwvvs5g |
| CitedBy_id | crossref_primary_10_51847_Hsll58k7kS crossref_primary_10_1038_s41392_024_01958_2 crossref_primary_10_3390_medicina59050934 crossref_primary_10_1021_acschemneuro_4c00153 crossref_primary_10_3389_fphar_2025_1515864 crossref_primary_10_1016_j_ijcard_2024_132110 crossref_primary_10_1371_journal_pone_0302818 crossref_primary_10_1007_s12011_024_04139_y crossref_primary_10_1111_imr_70003 crossref_primary_10_1016_j_micpath_2024_106717 |
| Cites_doi | 10.1056/NEJMoa2002032 10.1016/j.cmi.2021.11.007 10.1136/rmdopen-2020-001455 10.1136/bmj.m3379 10.1038/nature04516 10.2174/1381612824666180116095658 10.1007/s12016-021-08908-8 10.1111/sji.12998 10.1007/s11886-021-01589-x 10.1007/s00011-022-01540-y 10.1016/S2213-2600(21)00222-8 10.1074/jbc.M115.659029 10.1007/s00011-020-01413-2 10.1161/CIRCULATIONAHA.120.050560 10.1016/j.cmi.2022.08.013 10.3390/jcm11092615 10.1016/j.atherosclerosis.2021.08.005 10.1038/s41591-020-1051-9 10.1016/S2213-2600(21)00435-5 10.1080/07853890.2022.2096919 10.1016/j.dsx.2022.102395 10.1084/jem.20201707 10.1136/annrheumdis-2020-219174 10.1084/jem.20082481 10.1016/j.cytogfr.2011.10.001 10.1038/s41366-020-0598-3 10.1016/S1359-6101(97)00023-3 10.1042/CS20160090 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG. The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG. – notice: The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7T5 7T7 7TM 7TO 7U9 7X7 7XB 88E 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA BENPR C1K CCPQU FR3 FYUFA GHDGH H94 K9. M0S M1P M7N P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM |
| DOI | 10.1007/s00011-023-01718-y |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts Technology Research Database ProQuest One Academic Middle East (New) Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Oncogenes and Growth Factors Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1420-908X |
| EndPage | 899 |
| ExternalDocumentID | PMC10013297 36917217 10_1007_s00011_023_01718_y |
| Genre | Randomized Controlled Trial Journal Article |
| GrantInformation_xml | – fundername: Conselho Nacional de Desenvolvimento Científico e Tecnológico grantid: 425075/2016-8 funderid: http://dx.doi.org/10.13039/501100003593 – fundername: Fundação de Amparo à Pesquisa do Estado de São Paulo grantid: 2020/05288-6; 2013/08216-2; 2013/08216-2; 2013/08216-2; 2020/04964-8; 2013/08216-2; 2020/04826-4 funderid: http://dx.doi.org/10.13039/501100001807 – fundername: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior funderid: http://dx.doi.org/10.13039/501100002322 – fundername: Fundação de Amparo à Pesquisa do Estado de São Paulo grantid: 2020/04964-8 – fundername: Conselho Nacional de Desenvolvimento Científico e Tecnológico grantid: 425075/2016-8 – fundername: Fundação de Amparo à Pesquisa do Estado de São Paulo grantid: 2020/05288-6 – fundername: Fundação de Amparo à Pesquisa do Estado de São Paulo grantid: 2013/08216-2 – fundername: Fundação de Amparo à Pesquisa do Estado de São Paulo grantid: 2020/04826-4 – fundername: ; – fundername: ; grantid: 2020/05288-6; 2013/08216-2; 2013/08216-2; 2013/08216-2; 2020/04964-8; 2013/08216-2; 2020/04826-4 – fundername: ; grantid: 425075/2016-8 |
| GroupedDBID | --- -4W -56 -5G -BR -EM -Y2 -~C .55 .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 2.D 203 28- 29I 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3O- 3SX 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67N 67Z 6NX 78A 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABOCM ABPLI ABQBU ABQSL ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACZOJ ADBBV ADHIR ADIMF ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYPR ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EN4 EPAXT ESBYG FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ IHE IJ- IKXTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- N2Q NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P PF0 PKN PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZN T13 T16 TEORI TSG TSK TSV TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK6 WK8 X7M Y6R YLTOR Z45 Z7U Z7W Z82 Z87 Z8O Z8Q Z8V Z91 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7QL 7T5 7T7 7TM 7TO 7U9 7XB 8FD 8FK ABRTQ C1K FR3 H94 K9. M7N P64 PJZUB PKEHL PPXIY PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c475t-3a83aad7957cfd51d930f6cb9a3bbea11577ab7a2ba5e8013857e2a9451a98c93 |
| IEDL.DBID | U2A |
| ISSN | 1023-3830 1420-908X |
| IngestDate | Thu Aug 21 18:37:36 EDT 2025 Tue Aug 05 10:54:16 EDT 2025 Sat Jul 26 02:34:29 EDT 2025 Wed Feb 19 02:23:12 EST 2025 Tue Jul 01 01:43:54 EDT 2025 Thu Apr 24 23:08:03 EDT 2025 Fri Feb 21 02:44:37 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | COVID-19 Inflammasome Colchicine Cytokines |
| Language | English |
| License | 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c475t-3a83aad7957cfd51d930f6cb9a3bbea11577ab7a2ba5e8013857e2a9451a98c93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 Responsible Editor: John Di Battista. |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC10013297 |
| PMID | 36917217 |
| PQID | 2815842553 |
| PQPubID | 24296 |
| PageCount | 5 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10013297 proquest_miscellaneous_2786812354 proquest_journals_2815842553 pubmed_primary_36917217 crossref_citationtrail_10_1007_s00011_023_01718_y crossref_primary_10_1007_s00011_023_01718_y springer_journals_10_1007_s00011_023_01718_y |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-05-01 |
| PublicationDateYYYYMMDD | 2023-05-01 |
| PublicationDate_xml | – month: 05 year: 2023 text: 2023-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: Switzerland – name: New York |
| PublicationSubtitle | Official Journal of: The International Association of Inflammation Societies + The European Histamine Research Society |
| PublicationTitle | Inflammation research |
| PublicationTitleAbbrev | Inflamm. Res |
| PublicationTitleAlternate | Inflamm Res |
| PublicationYear | 2023 |
| Publisher | Springer International Publishing Springer Nature B.V |
| Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
| References | Vecchié, Del Buono, Chiabrando, Dentali, Abbate, Bonaventura (CR25) 2021; 23 (CR18) 2021; 9 Anka, Tahir, Abubakar (CR2) 2021; 93 Demidowich, Levine, Apps (CR26) 2020; 44 Del Valle, Kim-Schulze, Huang (CR3) 2020; 26 Reyes, Hu, Teperman (CR7) 2021; 80 Jin, Cai, Cheng (CR15) 2020; 7 Guan, Ni, Hu (CR1) 2020; 382 Bartoletti, Azap, Barac (CR13) 2022; 28 Tardif, Bouabdallaoui, L'Allier (CR17) 2021; 9 Robertson, Martinez, Payet (CR28) 2016; 130 Lopes, Bonjorno, Giannini (CR8) 2021; 7 Alfaidi, Wilson, Daigneault (CR19) 2015; 290 Rodrigues, de Sá, Ishimoto (CR4) 2021; 218 Bonaventura, Vecchié, Dagna, Tangianu, Abbate, Dentali (CR16) 2022; 71 Lan, Hsu, Lai (CR11) 2022; 54 Toldo, Bussani, Nuzzi (CR5) 2021; 70 Lamontagne, Agarwal, Rochwerg (CR12) 2020; 370 Liantinioti, Argyris, Protogerou, Vlachoyiannopoulos (CR6) 2018; 24 Toro-Huamanchumo, Benites-Meza, Mamani-García (CR9) 2022; 11 Lopez-Castejon, Brough (CR22) 2011; 22 Lachmann, Lowe, Felix (CR21) 2009; 206 Martinon, Pétrilli, Mayor (CR29) 2006; 440 Bartoletti, Azap, Barac (CR14) 2022; 28 Dinarello (CR20) 1997; 8 Qin, He, Yang (CR27) 2023; 64 Opstal, Hoogeveen, Fiolet (CR24) 2020; 142 Silvis, Fiolet, Opstal (CR23) 2021; 334 Zein, Raffaello (CR10) 2022; 16 M Bartoletti (1718_CR14) 2022; 28 DM Del Valle (1718_CR3) 2020; 26 RECOVERY Collaborative Group (1718_CR18) 2021; 9 S Toldo (1718_CR5) 2021; 70 SH Lan (1718_CR11) 2022; 54 MI Lopes (1718_CR8) 2021; 7 F Lamontagne (1718_CR12) 2020; 370 AP Demidowich (1718_CR26) 2020; 44 M Alfaidi (1718_CR19) 2015; 290 A Vecchié (1718_CR25) 2021; 23 AFMZ Zein (1718_CR10) 2022; 16 S Robertson (1718_CR28) 2016; 130 M Bartoletti (1718_CR13) 2022; 28 G Lopez-Castejon (1718_CR22) 2011; 22 CJ Toro-Huamanchumo (1718_CR9) 2022; 11 TSJ Opstal (1718_CR24) 2020; 142 CA Dinarello (1718_CR20) 1997; 8 A Bonaventura (1718_CR16) 2022; 71 TS Rodrigues (1718_CR4) 2021; 218 Y-H Jin (1718_CR15) 2020; 7 HJ Lachmann (1718_CR21) 2009; 206 WJ Guan (1718_CR1) 2020; 382 AZ Reyes (1718_CR7) 2021; 80 MJM Silvis (1718_CR23) 2021; 334 AU Anka (1718_CR2) 2021; 93 G Liantinioti (1718_CR6) 2018; 24 JC Tardif (1718_CR17) 2021; 9 R Qin (1718_CR27) 2023; 64 F Martinon (1718_CR29) 2006; 440 |
| References_xml | – volume: 382 start-page: 1708 year: 2020 end-page: 1720 ident: CR1 article-title: Clinical characteristics of coronavirus disease 2019 in China publication-title: N Engl J Med doi: 10.1056/NEJMoa2002032 – volume: 28 start-page: 222 year: 2022 end-page: 238 ident: CR13 article-title: ESCMID COVID-19 living guidelines: drug treatment and clinical management publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2021.11.007 – volume: 7 year: 2021 ident: CR8 article-title: Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial publication-title: RMD Open doi: 10.1136/rmdopen-2020-001455 – volume: 370 year: 2020 ident: CR12 article-title: A living WHO guideline on drugs for covid-19 publication-title: BMJ doi: 10.1136/bmj.m3379 – volume: 440 start-page: 237 year: 2006 end-page: 241 ident: CR29 article-title: Gout-associated uric acid crystals activate the NALP3 inflammasome publication-title: Nature doi: 10.1038/nature04516 – volume: 24 start-page: 690 year: 2018 end-page: 694 ident: CR6 article-title: The role of colchicine in the treatment of autoinflammatory diseases publication-title: Curr Pharm Des doi: 10.2174/1381612824666180116095658 – volume: 64 start-page: 33 year: 2023 end-page: 65 ident: CR27 article-title: Identification of parameters representative of immune dysfunction in patients with severe and fatal COVID-19 infection: a systematic review and meta-analysis publication-title: Clin Rev Allergy Immunol doi: 10.1007/s12016-021-08908-8 – volume: 93 year: 2021 ident: CR2 article-title: Coronavirus disease 2019 (COVID-19): an overview of the immunopathology, serological diagnosis and management publication-title: Scand J Immunol doi: 10.1111/sji.12998 – volume: 7 start-page: 4 year: 2020 ident: CR15 article-title: A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) publication-title: Mil Med Res – volume: 23 start-page: 157 year: 2021 ident: CR25 article-title: Interleukin-1 and the NLRP3 inflammasome in pericardial disease publication-title: Curr Cardiol Rep doi: 10.1007/s11886-021-01589-x – volume: 71 start-page: 293 year: 2022 end-page: 307 ident: CR16 article-title: Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation publication-title: Inflamm Res doi: 10.1007/s00011-022-01540-y – volume: 9 start-page: 924 year: 2021 end-page: 932 ident: CR17 article-title: Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(21)00222-8 – volume: 290 start-page: 24067 year: 2015 end-page: 24078 ident: CR19 article-title: Neutrophil elastase promotes interleukin-1β secretion from human coronary endothelium publication-title: J Biol Chem doi: 10.1074/jbc.M115.659029 – volume: 70 start-page: 7 year: 2021 end-page: 10 ident: CR5 article-title: Inflammasome formation in the lungs of patients with fatal COVID-19 publication-title: Inflamm Res doi: 10.1007/s00011-020-01413-2 – volume: 142 start-page: 1996 issue: 20 year: 2020 end-page: 1998 ident: CR24 article-title: Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease: a LoDoCo2 proteomic substudy publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.050560 – volume: 28 start-page: 1578 year: 2022 end-page: 1590 ident: CR14 article-title: European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2022.08.013 – volume: 11 start-page: 2615 year: 2022 ident: CR9 article-title: Efficacy of colchicine in the treatment of COVID-19 patients: a systematic review and meta-analysis publication-title: J Clin Med doi: 10.3390/jcm11092615 – volume: 334 start-page: 93 year: 2021 end-page: 100 ident: CR23 article-title: Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: a LoDoCo2 biomarker substudy publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2021.08.005 – volume: 26 start-page: 1636 year: 2020 end-page: 1643 ident: CR3 article-title: An inflammatory cytokine signature predicts COVID-19 severity and survival publication-title: Nat Med doi: 10.1038/s41591-020-1051-9 – volume: 9 start-page: 1419 year: 2021 end-page: 1426 ident: CR18 article-title: Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(21)00435-5 – volume: 54 start-page: 1956 year: 2022 end-page: 1965 ident: CR11 article-title: Effect of colchicine on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials publication-title: Ann Med doi: 10.1080/07853890.2022.2096919 – volume: 16 year: 2022 ident: CR10 article-title: Effect of colchicine on mortality in patients with COVID-19—a systematic review and meta-analysis publication-title: Diabetes Metab Syndr doi: 10.1016/j.dsx.2022.102395 – volume: 218 year: 2021 ident: CR4 article-title: Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients publication-title: J Exp Med doi: 10.1084/jem.20201707 – volume: 80 start-page: 550 year: 2021 end-page: 557 ident: CR7 article-title: Anti-inflammatory therapy for COVID-19 infection: the case for colchicine publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2020-219174 – volume: 206 start-page: 1029 year: 2009 end-page: 1036 ident: CR21 article-title: In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes publication-title: J Exp Med doi: 10.1084/jem.20082481 – volume: 22 start-page: 189 year: 2011 end-page: 195 ident: CR22 article-title: Understanding the mechanism of IL-1β secretion publication-title: Cytokine Growth Factor Rev doi: 10.1016/j.cytogfr.2011.10.001 – volume: 44 start-page: 1793 year: 2020 end-page: 1799 ident: CR26 article-title: Colchicine’s effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial publication-title: Int J Obes doi: 10.1038/s41366-020-0598-3 – volume: 8 start-page: 253 year: 1997 end-page: 265 ident: CR20 article-title: Interleukin-1 publication-title: Cytokine Growth Factor Rev doi: 10.1016/S1359-6101(97)00023-3 – volume: 130 start-page: 1237 year: 2016 end-page: 1246 ident: CR28 article-title: Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation publication-title: Clin Sci doi: 10.1042/CS20160090 – volume: 7 start-page: 4 year: 2020 ident: 1718_CR15 publication-title: Mil Med Res – volume: 334 start-page: 93 year: 2021 ident: 1718_CR23 publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2021.08.005 – volume: 8 start-page: 253 year: 1997 ident: 1718_CR20 publication-title: Cytokine Growth Factor Rev doi: 10.1016/S1359-6101(97)00023-3 – volume: 54 start-page: 1956 year: 2022 ident: 1718_CR11 publication-title: Ann Med doi: 10.1080/07853890.2022.2096919 – volume: 206 start-page: 1029 year: 2009 ident: 1718_CR21 publication-title: J Exp Med doi: 10.1084/jem.20082481 – volume: 23 start-page: 157 year: 2021 ident: 1718_CR25 publication-title: Curr Cardiol Rep doi: 10.1007/s11886-021-01589-x – volume: 7 year: 2021 ident: 1718_CR8 publication-title: RMD Open doi: 10.1136/rmdopen-2020-001455 – volume: 130 start-page: 1237 year: 2016 ident: 1718_CR28 publication-title: Clin Sci doi: 10.1042/CS20160090 – volume: 44 start-page: 1793 year: 2020 ident: 1718_CR26 publication-title: Int J Obes doi: 10.1038/s41366-020-0598-3 – volume: 71 start-page: 293 year: 2022 ident: 1718_CR16 publication-title: Inflamm Res doi: 10.1007/s00011-022-01540-y – volume: 28 start-page: 222 year: 2022 ident: 1718_CR13 publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2021.11.007 – volume: 22 start-page: 189 year: 2011 ident: 1718_CR22 publication-title: Cytokine Growth Factor Rev doi: 10.1016/j.cytogfr.2011.10.001 – volume: 440 start-page: 237 year: 2006 ident: 1718_CR29 publication-title: Nature doi: 10.1038/nature04516 – volume: 80 start-page: 550 year: 2021 ident: 1718_CR7 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2020-219174 – volume: 64 start-page: 33 year: 2023 ident: 1718_CR27 publication-title: Clin Rev Allergy Immunol doi: 10.1007/s12016-021-08908-8 – volume: 290 start-page: 24067 year: 2015 ident: 1718_CR19 publication-title: J Biol Chem doi: 10.1074/jbc.M115.659029 – volume: 9 start-page: 924 year: 2021 ident: 1718_CR17 publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(21)00222-8 – volume: 218 year: 2021 ident: 1718_CR4 publication-title: J Exp Med doi: 10.1084/jem.20201707 – volume: 93 year: 2021 ident: 1718_CR2 publication-title: Scand J Immunol doi: 10.1111/sji.12998 – volume: 24 start-page: 690 year: 2018 ident: 1718_CR6 publication-title: Curr Pharm Des doi: 10.2174/1381612824666180116095658 – volume: 26 start-page: 1636 year: 2020 ident: 1718_CR3 publication-title: Nat Med doi: 10.1038/s41591-020-1051-9 – volume: 70 start-page: 7 year: 2021 ident: 1718_CR5 publication-title: Inflamm Res doi: 10.1007/s00011-020-01413-2 – volume: 382 start-page: 1708 year: 2020 ident: 1718_CR1 publication-title: N Engl J Med doi: 10.1056/NEJMoa2002032 – volume: 142 start-page: 1996 issue: 20 year: 2020 ident: 1718_CR24 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.050560 – volume: 16 year: 2022 ident: 1718_CR10 publication-title: Diabetes Metab Syndr doi: 10.1016/j.dsx.2022.102395 – volume: 11 start-page: 2615 year: 2022 ident: 1718_CR9 publication-title: J Clin Med doi: 10.3390/jcm11092615 – volume: 9 start-page: 1419 year: 2021 ident: 1718_CR18 publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(21)00435-5 – volume: 28 start-page: 1578 year: 2022 ident: 1718_CR14 publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2022.08.013 – volume: 370 year: 2020 ident: 1718_CR12 publication-title: BMJ doi: 10.1136/bmj.m3379 |
| SSID | ssj0008282 |
| Score | 2.4399066 |
| Snippet | Objective
To evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19.
Methods
We... To evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19. We present a post hoc... ObjectiveTo evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19.MethodsWe... To evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19.OBJECTIVETo evaluate... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 895 |
| SubjectTerms | Allergology Biomedical and Life Sciences Biomedicine Brief Report Caspase-1 Clinical trials Colchicine Colchicine - therapeutic use Coronaviruses COVID-19 Cytokine storm Dermatology Humans IL-1β Immunology Inflammasomes Inflammasomes - metabolism Interleukin 18 Interleukin-1beta - metabolism Neurology NLR Family, Pyrin Domain-Containing 3 Protein - metabolism NLR Proteins Patients Pharmacology/Toxicology Placebos RBR RBR8jyhxh Rheumatology Serum levels |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BuXBBUF6hBRkJ9cJarOM4tk8ILa1aVMoKtWhv0STrqEhtUprtYf99PY43q6Vqj5FtJc6MPe9vAD55EWecqahHmDdXM1ELjg5TblOFeW3GZR3Aqn-e5Idn2Y-ZmkWHWxfTKld3Yrio521FPvIvqRGKQkZKfr36x6lrFEVXYwuNx_CEoMsopUvPBoOL0Nn6aGcqubfExrFoJpTOBWWI0wghxhi-3BRMd7TNu0mT_0VOg0A6eA7PoibJvvWkfwGPXLMNe9Meino5YqfryqpuxPbYdA1SvXwJx5P2gtqgeCWTXRN8q-uY1wUZ1Tn0XlrW1uzk-PdUMs-Enm8usWsvnX9gk19_jr5zYVkEZe1ewdnB_unkkMfOCrzKtFpwiUYizrVVuqrnSsytHNd5VVqUZemQAHg0lhrTEpUzFMxU2qVoMyXQmsrK17DVtI17CyyTThqUzmuemDnMTWb9pWGFRC8fdSUTEKvfWlQRdpy6X1wUA2ByIEXhSVEEUhTLBD4Pa6560I0HZ--uqFXEA9gVa3ZJ4OMw7I8OxUOwce2Nn6MNoa9JlSXwpifu8DqZWzKOdQJmg-zDBILl3hxp_p4HeG4R4lfWLx2tOGT9Xfdv493D29iBp2ngVsq13IWtxfWNe-_1oUX5ITD9LbHVBMA priority: 102 providerName: ProQuest |
| Title | Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients |
| URI | https://link.springer.com/article/10.1007/s00011-023-01718-y https://www.ncbi.nlm.nih.gov/pubmed/36917217 https://www.proquest.com/docview/2815842553 https://www.proquest.com/docview/2786812354 https://pubmed.ncbi.nlm.nih.gov/PMC10013297 |
| Volume | 72 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED-x7YUXxDeFURkJ7YVaauI4th_b0jJglGpaUXmKLqmjIW0JWrqH_vecnY-qDJB4siKfEyd39t3lfL8DeEsqTluduRph5K5GQR5wtBhyE0qMcz1Mcw9W_WUeny6jTyu5apLCqva0exuS9Dt1l-zmzRdOOoY7jBfNtwdwJJ3vTlK8DEfd_ks-RB3jJEryv4ZNqsyf77Gvju7YmHePSv4WL_VqaPYQHjT2IxvVDH8E92zxGE4WNQD1dsAudvlU1YCdsMUOmnr7BM4m5ZUrfkKmJbtxoK22YmQBMpfdUP-bZWXO5mfnC8FI9EharrEqry1dsMnXbx_f88CwBoq1egrL2fRicsqbego8i5TccIFaIK6VkSrL1zJYGzHM4yw1KNLUooPdUZgqDFOUVrsQplQ2RBPJAI3OjHgGh0VZ2BfAImGFRmHJ3sTIYqwjQ1uFCQSSVlSZ6EHQftYka8DGXc2Lq6SDSfasSIgViWdFsu3Bu27Mzxpq45_Uxy23kmbZVUmoA-niipIm8KbrpgXjoiBY2PKWaJR2mGtCRj14XjO3e5yIjXOJVQ_0Hts7AgfGvd9T_Lj0oNyBj1oZGjpoJWQ3r7-_xsv_I38F90Mvve7E5TEcbm5u7WuyijZpHw7USvXhaDQbj-eu_fD985Ta8XS-OO_7JfILk6EHng |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Nb9MwFH-augNcEN-EDTAS7EItmjhO7ANC0G1qWVeqqUO7ZU7qCKQt2ZZOKP8UfyPv5asqE7vtGNlWEr9vP7_fA3iHJk5ZlVCPMAxXfTd1ubHG49qTJkjVIE4rsOrDaTA69r-dyJMN-NPWwtC1ylYnVop6kSd0Rv7RU66klJEUny8uOXWNouxq20KjZosDW_7GkK34NN5F-r73vP29-XDEm64CPPFDueTCKGHMItQyTNKFdBdaDNIgibURcWwNgc-EJg6NFxtpFSXyZGg9o33pGq0SAl9Clb_pCwxlerD5dW86O-p0P8YvdX7VExxjv0FTplMV61XuF6cRwqhRvFw3hTf825vXNP_J1VYmcP8hPGh8V_alZrZHsGGzx7Azq8Gvyz6br2q5ij7bYbMVLHb5BCbD_Iwar6Bby64IMNYWDL1PRpUV9bkwy1M2nRzNBEO2R049N0V-bvGBDb__GO9yV7MGBrZ4Csd3suvPoJflmX0BzBdWKCMs-rrGtyZQvkY1pV1h0CKHiXDAbbc1Shqgc-q3cRZ1EM0VKSIkRVSRIiod-NCtuahhPm6dvd1SK2pEvohWDOrA224YhZUyMCaz-TXOCRXhvQnpO_C8Jm73OhFoCsdDB9Qa2bsJBAS-PpL9-lkBgrtVxkzj0n7LIavv-v9vvLz9N97AvdH8cBJNxtODLbjvVZxLNz23obe8urav0Btbxq8bEWBwetdS9xewVEOL |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemISFeEN-EDTAS7IVaq-O4th8QQi3Vykqp0Ib6ljmpI5C2ZFs6ofxr_HXcOR9VmdjbHiPbSuL78J3v7neEvIUjTjudYo8wcFcjnnFmnQ2ZCaUdZLqfZB6s-utscHAcfVnIxRb509bCYFplqxO9ol4WKd6R74eaSwwZSbGfNWkR89H44_kFww5SGGlt22nULHLoqt_gvpUfJiOg9bswHH8-Gh6wpsMASyMlV0xYLaxdKiNVmi0lXxrRzwZpYqxIEmcRiEbZRNkwsdJpDOpJ5UJrIsmt0SkCMYH6v6OE5ChjatE5e4gMV0daQ8HAC-w3BTu-bM8bYgxHEK1Gs2rzULxm6V5P2PwnausPw_EDcr-xYumnmu0eki2XPyJ78xoGu-rRo3VVV9mje3S-BsiuHpPpsDjFFixg4NJLhI51JQU7lGKNRX1DTIuMzqbf54KCAADPntmyOHPwQIfffkxGjBvaAMKWT8jxrez5U7KdF7l7TmgknNBWOLB6beTsQEcGFJbhwsLZrFIREN5ua5w2kOfYeeM07sCaPSliIEXsSRFXAXnfrTmvAT9unL3bUituhL-M16wakDfdMIgtxmJs7oormKM0Ir8JGQXkWU3c7nViYNAxVwHRG2TvJiAk-OZI_uunhwbnPnZmYGmv5ZD1d_3_N17c_BuvyV2QtXg6mR3ukHuhZ1xM-dwl26vLK_cSzLJV8srzPyUnty1wfwFXcUZb |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Colchicine+reduces+the+activation+of+NLRP3+inflammasome+in+COVID-19+patients&rft.jtitle=Inflammation+research&rft.au=Amaral%2C+N.+B.&rft.au=Rodrigues%2C+T.+S.&rft.au=Giannini%2C+M.+C.&rft.au=Lopes%2C+M.+I.&rft.date=2023-05-01&rft.issn=1023-3830&rft.eissn=1420-908X&rft.volume=72&rft.issue=5&rft.spage=895&rft.epage=899&rft_id=info:doi/10.1007%2Fs00011-023-01718-y&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00011_023_01718_y |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1023-3830&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1023-3830&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1023-3830&client=summon |